Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study

Background: Intracranial hemorrhage (ICH) is associated with high mortality and morbidity, especially in patients under anticoagulative treatment. Andexanet alfa (AA) is a modified recombinant form of human factor Xa (FXa) developed for reversal of FXa-inhibitors, e.g., in the event of ICH, but expe...

Full description

Bibliographic Details
Main Authors: Sebastian Rauch, Hans-Peter Müller, Jens Dreyhaupt, Albert C. Ludolph, Jan Kassubek, Katharina Althaus
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Journal of Clinical Medicine
Subjects:
coagulants
factor Xa inhibitors
hemorrhage
intracranial hemorrhages
antidote
andexanet alfa
Online Access:https://www.mdpi.com/2077-0383/11/12/3399

Similar Items

Similar Items